AEGON ASSET MANAGEMENT UK Plc Acquires 6,968 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

AEGON ASSET MANAGEMENT UK Plc increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 267,474 shares of the biopharmaceutical company’s stock after buying an additional 6,968 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc’s holdings in Gilead Sciences were worth $24,701,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bellevue Group AG raised its stake in Gilead Sciences by 18.2% during the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after buying an additional 7,093 shares during the last quarter. Quantinno Capital Management LP increased its position in Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after acquiring an additional 48,910 shares during the last quarter. Legal & General Group Plc lifted its holdings in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after acquiring an additional 93,068 shares during the period. IRON Financial LLC purchased a new position in Gilead Sciences in the third quarter worth about $830,000. Finally, Capital Investment Advisors LLC grew its stake in shares of Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after purchasing an additional 9,791 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

Shares of GILD opened at $93.07 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The stock has a market capitalization of $115.99 billion, a PE ratio of 1,034.11, a P/E/G ratio of 1.31 and a beta of 0.18. The company’s fifty day moving average is $91.74 and its 200 day moving average is $84.86. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.29 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GILD. Barclays raised their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Truist Financial raised their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Daiwa America raised Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Insider Activity

In related news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.